CleavPredict: A Platform for Reasoning about Matrix Metalloproteinases Proteolytic Events

CleavPredict (http://cleavpredict.sanfordburnham.org) is a Web server for substrate cleavage prediction for matrix metalloproteinases (MMPs). It is intended as a computational platform aiding the scientific community in reasoning about proteolytic events. CleavPredict offers in silico prediction of cleavage sites specific for 11 human MMPs. The prediction method employs the MMP specific position weight matrices (PWMs) derived from statistical analysis of high-throughput phage display experimental results. To augment the substrate cleavage prediction process, CleavPredict provides information about the structural features of potential cleavage sites that influence proteolysis. These include: secondary structure, disordered regions, transmembrane domains, and solvent accessibility. The server also provides information about subcellular location, co-localization, and co-expression of proteinase and potential substrates, along with experimentally determined positions of single nucleotide polymorphism (SNP), and posttranslational modification (PTM) sites in substrates. All this information will provide the user with perspectives in reasoning about proteolytic events. CleavPredict is freely accessible, and there is no login required.

[1]  A. Strongin,et al.  Internal Cleavages of the Autoinhibitory Prodomain Are Required for Membrane Type 1 Matrix Metalloproteinase Activation, although Furin Cleavage Alone Generates Inactive Proteinase* , 2010, The Journal of Biological Chemistry.

[2]  A. Strongin,et al.  Matrix metalloproteinase proteolysis of the mycobacterial HSP65 protein as a potential source of immunogenic peptides in human tuberculosis , 2011, The FEBS journal.

[3]  A. Strongin,et al.  The Wnt/Planar Cell Polarity Protein-tyrosine Kinase-7 (PTK7) Is a Highly Efficient Proteolytic Target of Membrane Type-1 Matrix Metalloproteinase , 2010, The Journal of Biological Chemistry.

[4]  G. Schiavo,et al.  Bacterial toxins with intracellular protease activity. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[5]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[6]  Gillian Murphy,et al.  Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? , 2008, Nature Clinical Practice Rheumatology.

[7]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[8]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[9]  Jeffrey W. Smith,et al.  CutDB: a proteolytic event database , 2006, Nucleic Acids Res..

[10]  A. Strongin,et al.  Substrate Cleavage Profiling Suggests a Distinct Function of Bacteroides fragilis Metalloproteinases (Fragilysin and Metalloproteinase II) at the Microbiome-Inflammation-Cancer Interface* , 2013, The Journal of Biological Chemistry.

[11]  Piotr Cieplak,et al.  Sequence‐derived structural features driving proteolytic processing , 2014, Proteomics.

[12]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. 1967. , 2012, Biochemical and biophysical research communications.

[13]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[14]  Kengo Kinoshita,et al.  COXPRESdb: a database of comparative gene coexpression networks of eleven species for mammals , 2012, Nucleic Acids Res..

[15]  Carine Munaut,et al.  MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  C. Brinckerhoff,et al.  Matrix metalloproteinases: role in arthritis. , 2006, Frontiers in bioscience : a journal and virtual library.

[17]  D. Critchley.  Smurf1 zaps the talin head , 2009, Nature Cell Biology.

[18]  Ying Zhang,et al.  Structural determinants of limited proteolysis. , 2011, Journal of proteome research.

[19]  G J Barton,et al.  Application of multiple sequence alignment profiles to improve protein secondary structure prediction , 2000, Proteins.

[20]  Hsien-Da Huang,et al.  dbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications , 2012, Nucleic Acids Res..

[21]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[22]  Geoffrey I. Webb,et al.  PROSPER: An Integrated Feature-Based Tool for Predicting Protease Substrate Cleavage Sites , 2012, PloS one.

[23]  Alex Bateman,et al.  MEROPS: the database of proteolytic enzymes, their substrates and inhibitors , 2011, Nucleic Acids Res..

[24]  C. López-Otín,et al.  Proteases: Multifunctional Enzymes in Life and Disease* , 2008, Journal of Biological Chemistry.

[25]  R. Khokha,et al.  Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[26]  Ian H. Witten,et al.  Data mining: practical machine learning tools and techniques, 3rd Edition , 1999 .

[27]  G. Salvesen,et al.  Caspases: Intracellular Signaling by Proteolysis , 1997, Cell.

[28]  Christopher M Overall,et al.  Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. , 2009, Biochemistry.

[29]  T. Ley,et al.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Hubbard,et al.  The structural aspects of limited proteolysis of native proteins. , 1998, Biochimica et biophysica acta.

[31]  A. Strongin,et al.  High-Resolution Analysis and Functional Mapping of Cleavage Sites and Substrate Proteins of Furin in the Human Proteome , 2013, PloS one.

[32]  J. Delaissé,et al.  A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. , 2004, Bone.

[33]  Jakub Wlodarczyk,et al.  MMP9: a novel function in synaptic plasticity. , 2012, The international journal of biochemistry & cell biology.

[34]  Michele Magrane,et al.  UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.

[35]  B. Bresnihan,et al.  Synovial tissue inflammation in early and late osteoarthritis , 2005, Annals of the rheumatic diseases.

[36]  Alexander Fraser,et al.  Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. , 2003, Arthritis and rheumatism.

[37]  D. Zukor,et al.  Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. , 2002, Arthritis & Rheumatism.

[38]  Oliver Schilling,et al.  Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites , 2008, Nature Biotechnology.

[39]  R. W. Rauser,et al.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[41]  S. M. Park,et al.  A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. , 2004, Biochimica et biophysica acta.

[42]  Christopher M. Overall,et al.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting , 2009, Nature Reviews Drug Discovery.

[43]  A. Newby,et al.  Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. , 2006, Cardiovascular research.

[44]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[45]  Andrew C. R. Martin.  Databases and ontologies Mapping PDB chains to UniProtKB entries , 2005 .

[46]  A. Strongin,et al.  New Details of HCV NS3/4A Proteinase Functionality Revealed by a High-Throughput Cleavage Assay , 2012, PloS one.

[47]  C. Rice,et al.  Structure of the catalytic domain of the hepatitis C virus NS2-3 protease , 2006, Nature.

[48]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[49]  Andrew J. Ewald,et al.  Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.

[50]  J. Weidner,et al.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. , 1997, The Journal of clinical investigation.

[51]  A. Churg,et al.  Matrix metalloproteinases in COPD , 2011, European Respiratory Journal.

[52]  Jeffrey W. Smith,et al.  Basis for substrate recognition and distinction by matrix metalloproteinases , 2014, Proceedings of the National Academy of Sciences.

[53]  Linda Troeberg,et al.  Proteases involved in cartilage matrix degradation in osteoarthritis. , 2012, Biochimica et biophysica acta.

[54]  P. Opolon,et al.  AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. , 2001, Human gene therapy.

[55]  Piotr Cieplak,et al.  Matrix Metalloproteinase Proteolysis of the Myelin Basic Protein Isoforms Is a Source of Immunogenic Peptides in Autoimmune Multiple Sclerosis , 2009, PloS one.

[56]  M. Pepper.  Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[57]  A. Baker,et al.  Suppression of Atherosclerotic Plaque Progression and Instability by Tissue Inhibitor of Metalloproteinase-2: Involvement of Macrophage Migration and Apoptosis , 2006, Circulation.

[58]  P. Nurse,et al.  Regulating S Phase: CDKs, Licensing and Proteolysis , 1996, Cell.

[59]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[60]  R. Fritsche-Danielson,et al.  Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. , 2006, Cardiovascular research.

[61]  Alexander V. Diemand,et al.  The Swiss‐Prot variant page and the ModSNP database: A resource for sequence and structure information on human protein variants , 2004, Human mutation.

[62]  C. Libert,et al.  Matrix Metalloproteinases as Drug Targets in Infections Caused by Gram-Negative Bacteria and in Septic Shock , 2009, Clinical Microbiology Reviews.

[63]  A. Newby.  Metalloproteinases and vulnerable atherosclerotic plaques. , 2007, Trends in cardiovascular medicine.

[64]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[65]  Bernard F. Buxton,et al.  The DISOPRED server for the prediction of protein disorder , 2004, Bioinform..

[66]  S. Brunak,et al.  SignalP 4.0: discriminating signal peptides from transmembrane regions , 2011, Nature Methods.

[67]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[68]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[70]  E. Scanziani,et al.  BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  R. Carrell,et al.  Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis , 1985, Nature.

[72]  C. Overall,et al.  Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.

[73]  L. Castagnoli,et al.  mentha: a resource for browsing integrated protein-interaction networks , 2013, Nature Methods.

[74]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[75]  S. Itohara,et al.  Diminished corneal angiogenesis in gelatinase A‐deficient mice , 2001, FEBS letters.

[76]  Jeffrey W. Smith,et al.  Inflammatory Proprotein Convertase-Matrix Metalloproteinase Proteolytic Pathway in Antigen-presenting Cells as a Step to Autoimmune Multiple Sclerosis* , 2009, The Journal of Biological Chemistry.

[77]  A. Krogh,et al.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. , 2001, Journal of molecular biology.

[78]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[79]  High throughput substrate phage display for protease profiling. , 2009, Methods in molecular biology.

[80]  Sandra Lopez-Aviles,et al.  Cell Cycle: The Art of Multi-Tasking , 2010, Current Biology.

[81]  B. Strooper,et al.  The presenilins in Alzheimer's disease--proteolysis holds the key. , 1999, Science.